论文部分内容阅读
目的:观察重组人促红细胞生成素(r Hu EPO,促红素EPO)治疗维持性血液透析肝病患者肾性贫血的疗效。方法:收集2014年6―12月北京佑安医院血液净化中心维持性血液透析肝病患者68例,透析结束时皮下注射促红素,根据血红蛋白结果调整剂量,观察6个月内血红蛋白达标情况。每3月化验一次血红蛋白(HB)、红细胞压积(HCT)、血清铁(FE)、血清铁蛋白(FER)、转铁蛋白饱和度(TS)、白蛋白(ALB)、甲状旁腺激素(PTH)、尿素氮(BUN)。数据采用SPSS统计分析,所有计量资料采用·x±s表示,组间比较用t检验。结果:使用促红素治疗3个月及6个月,血红蛋白分别和治疗前比较,差异均有显著性(P<0.05),血红蛋白达标率64.71%;治疗6个月较治疗3个月血红蛋白水平比较,差异有显著性(P<0.05)。尿素氮清除率、甲状旁腺激素、血清铁、血清铁蛋白、转铁蛋白饱和度方面,3个月较0月比较,6个月较3个月比较,差异均无显著性。结论:促红素可以改善维持性血液透析肝病患者肾性贫血,提高患者的生存期和生活质量。
Objective: To observe the therapeutic effect of recombinant human erythropoietin (r Hu EPO) on renal anemia in patients with maintenance hemodialysis liver disease. Methods: Sixty-six patients with maintenance hemodialysis liver disease in Beijing You’an Hospital Blood Purification Center from June to December 2014 were collected. Erythropoietin was injected subcutaneously at the end of dialysis. The dosage of hemoglobin was adjusted according to hemoglobin results to observe the compliance of hemoglobin within 6 months. Blood samples were collected every three months and tested for hemoglobin (HB), hematocrit (HCT), serum iron (FE), serum ferritin (FER), transferrin saturation (TS), albumin (ALB), parathyroid hormone PTH), urea nitrogen (BUN). SPSS statistical analysis of data, all measurement data using x ± s, said t-test between groups. Results: The hemoglobin levels of three months and six months after treatment with erythropoietin were significantly different from those before treatment (P <0.05), and the standard of hemoglobin was 64.71%. The hemoglobin level The difference was significant (P <0.05). In the three months compared with the month of 0, urea nitrogen clearance rate, parathyroid hormone, serum iron, serum ferritin and transferrin saturation were not significantly different between 6 months and 3 months. Conclusion: Erythromycin can improve renal anemia in patients with maintenance hemodialysis liver disease and improve patients’ life span and quality of life.